Bray F, Ferlay J, Soerjomataram I, et al. Global cancerstatistics 2018: GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394-424.
Las cifras de Cáncer en España 2022. Sociedad española de oncología médica (SEOM).
Aebi S, Karlsson P, Wapnir IL. Locally advanced breast cancer. Breast 2022;62 (Suppl.1):S58-S62.
Dhanushkodi M, Sridevi V, Shanta V, et al. Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai. JCO Global Oncology 2021;7(7):767- 81.
Heil J, Kuerer HM, Pfob A, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol 2020;31(1):61-71.
Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97(3):188-94.
Rueth NM, Lin HY, Bedrosian I, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol 2014;32(19):2018-24.
Amin MB, Greene FL, Edge SB, et al. The EighthEdition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancerstaging. CA Cancer J Clin 2017;67:93-9.
Menta A, Fouad TM, Lucci A, et al. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. Surg Clin North Am 2018;98(4):787-800.
Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol 2018;25(7):1783-85.
Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011;22(3):515-23.
Wu SG, Zhang WW, Wang J, et al. Inflammatory breast cancer outcomes by breast cancer subtype: A population-based study. Future Oncol 2019;15(5):507-16.
Ravaioli A, Pasini G, Polselli A, et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 2002;72(1):53e60.
Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16(2):263e6.
Ali B, Mubarik F, Zahid N, et al. Clinicopathologic features predictive of distant metastasis in patients diagnosed with invasive breast cancer. JCO Glob Oncol 2020;6:1346e51.
Groheux D, Giacchetti S, Delord M, et al. 18FFDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 2013;54(1):5e11.
Song SE, Seo BK, Cho KR, et al. Preoperative tumor size measurement in breast cancer patients: which threshold is appropriate on computer-aided detection for breast MRI? Cancer Imaging 2020;20(1):32.
Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017;318(10):918-26.
Marino MA, Avendano D, Zapata P, et al. Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools. Oncologist 2020;25(2):e231-42.
Bedi DG, Krishnamurthy R, Krishnamurthy S, et al. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. AJR Am J Roentgenol 2008;191(3):646-52.
Heywang SH, Fenzl G, Hahn D, et al. MR imaging of the breast: Comparison with mammography and ultrasound. J Comput Assist Tomogr 1986;10:615-20.
Mann RM, Cho N, Moy L. Breast MRI: State of the Art. Radiology 2019;292(3):520-36.
Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin 2009;59(5):290-302.
Marino MA, Avendano D, Zapata P, et al. Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools. Oncologist 2020;25(2):e231-42.
Kuhl C, Kuhn W, Braun M, et al. Pre-operative staging of breast cancer with breast MRI: one step forward, two steps back? Breast 2007;16(Suppl.2):S34-44.
Polat DS, Evans WP, Dogan BE. Contrast-Enhanced Digital Mammography: Technique, Clinical Applications, and Pitfalls. AJR Am J Roentgenol 2020;215(5):1267-78.
Liberman L. Breast MR imaging in assessing extent of disease. Magn Reson Imaging Clin N Am 2006;14(3):339-49.
Jochelson MS, Lobbes MBI. Contrast-enhanced Mammography: State of the Art. Radiology 2021;299(1):36-48.
Lobbes MBI, Heuts EM, Moossdorff M, et al. Contrast enhanced mammography (CEM) versus magnetic resonance imaging (MRI) for staging of breast cancer: The pro CEM perspective. Eur J Radiol 2021;142:109883.
Balu-Maestro C, Chapellier C, Bleuse A, et al. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 2002;72(2):145-52.
Lobbes MB, Prevos R, Smidt M, et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging 2013;4(2):163-75.
Iima M, Honda M, Sigmund EE, et al. Diffusion MRI of the breast: Current status and future directions. J Magn Reson Imaging 2020;52(1):70-90.
Santamaría G, Bargalló X, Fernández PL, et al. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast- enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response. Radiology 2017;283(3):663-72.
Choi WJ, Kim HH, Cha JH, et al. Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients: Factors of radiologic-pathologic discordance. Eur J Radiol 2019;118:114-21.
Ko ES, Han BK, Kim RB, et al. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Annu Surg Oncol 2013;20:2562-8.
McGuire KP, Toro-Burguete J, Dang H, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 2011;18(11):3149-54.
Yu N, Leung VWY, Meterissian S. MRI Performance in Detecting pCR After Neoadjuvant Chemotherapy by Molecular Subtype of Breast Cancer. World J Surg 2019;43(9):2254-61.
Fallenberg EM, Dromain C, Diekmann F, et al. Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size. Eur Radiol 2014;24:256-64.
Lalji UC, Jeukens CR, Houben I, et al. Evaluation of low-energy contrast-enhanced spectral mammography images by comparing them to full-field digital mammography using EUREF image quality criteria. Eur Radiol 2015;25:2813-20.
Iotti V, Giorgi Rossi P. Contrast-enhanced mammography in Neoadjuvant therapy response monitoring. In Contrast-Enhanced Mammography. In: Lobbes MBI, Jochelson MS (editors). Springer: Cham (Switzerland); 2019. p. 133-60.
Feliciano Y, Mamtani A, Morrow M, et al. Do calcifications seen on mammography after Neoadjuvant chemotherapy for breast cancer always need to be excised? Annu Surg Oncol 2017;24:1492-8.
Fushimi A, Kudo R, Takeyama H. Do decreased breast microcalcifications after Neoadjuvant chemotherapy predict pathologic complete response? Clin Breast Cancer 2020;20:e82-8.
Jochelson MS, Lampen-Sachar K, Gibbons G, et al. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy? Annu Surg Oncol 2015;22:1490-5.
Iotti V, Ragazzi M, Besutti G, et al. Accuracy and Reproducibility of Contrast-Enhanced Mammography in the Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients with Calcifications in the Tumor Bed. Diagnostics (Basel) 2021;11(3):435.